Alnylam Pharmaceuticals focuses on diseases with unmet medical needs in four Strategic Therapeutic Areas (STArs): genetic medicines, cardiometabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases. Founded in 2002, Alnylam Pharmaceuticals is delivering on a bold vision to turn scientific possibility into reality, with a robust innovative therapeutics platform. Our local offices are located in Amsterdam.
